new approaches to decreasing preterm births with Makena (hydroxyprogesterone) and terbutaline
May 2011
Please see the November 2011 FDA statement concerning Makena.
One in eight babies is born prematurely in the United States.
Makena (mah-KEE-na) is the first drug APPROVED for reducing the risk of preterm birth...but it's not really new.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote